Honing in

The best combination of lipid-lowering drugs and which patients might benefit from antiplatelet therapy or anticoagulant therapy are among the unknowns in cardiovascular risk reduction in diabetes that Professor Miles Fisher would like resolved.

For his full take, listen to the latest in the series of ‘5 things we don’t yet know’.